乳腺浸润性导管癌分子亚型与临床病理特征及预后的关系  

Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis

作　　者：林敏[1] 陈忠清[1] 包芸[1] 李琼[1] 杜尊国[1] 许祖德[1] 唐峰[1] 

机构地区：[1]复旦大学附属华山医院病理科,上海200040

出　　处：《中华病理学杂志》2010年第6期372-376,共5页Chinese Journal of Pathology

摘　　要：目的 检测乳腺浸润性导管癌的临床病理特征及特定蛋白的表达情况,对其进行分型,探讨各哑型与预后的关系.方法 采用免疫组织化学EnVision法检测128例浸润性导管癌ER、PR、HER2和CK5/6的表达,参考文献报道的免疫分型方法 对其分型,并对HER2过表达型9例进行FISH检测.结果 ER、PR、HER2和CKS/6在本组128例浸润性导管癌中的阳性表达率分别为67%（86/128）、45%（58/128）、27%（34/128）和27%（34/128）,并将128例分为5种免疫哑型,管腔A型55%（70/128）,管腔B型20%（25/128）,HER2过表达型7%（9/128）,基底细胞样型10%（13/128）,无法分类型8%（11/128）.FISH检测HER2过表达型9例均为HER2基因扩增.各分子亚型间预后差异具有统计学意义,管腔A型预后最好,基底细胞型预后较差.多因素分析,乳腺癌临床分期和免疫分型是独立的预后因素.月经状态在乳腺癌各免疫亚型中的分布差异有统计学意义.结论 通过检测ER、PR、HER2和CK5/6的表达可以将乳腺浸润性导管癌分成具有不同生物学行为的5个免疫亚型,对于评估预后,指导治疗具有一定的意义.Objectives This study try to subclassify breast cancer into different prognostic subgroups according to immunohistochemical algorithm and discuss the relationship between subtypes and biological and clinical behavior and prognosis. Methods One hundred and twenty-eight cases of infiltrative ductal carcinoma were studied using immunohistochemical staining with an antibody panel of ER, PR, HER2 and CK5/6 and subclassified referring to previous reports, and the 9 cases of HER2 positive subtype were tested using FISH. Results The expression of ER, PR, HER2, and CK5/6 was detected in 67% ,45% ,27% and 27% cases , respectively. All cases were subclassified into five subgroups, with luminal A （55%）, luminal B （20%） , HER2 positive （7%） , basal-like （10%） and unclassied cases （8%）. Nine HER2 positive cases all showed amplification of HER2 gene. It was demonstrated that the luminal A group was associated with the best prognosis but the basal-like group worst by univariate analysis. Multivariate analysis demonstrated that both the clinical stage and immunohistochemical subtypes of tumor were related to overall survival. Menses status were different among these subtypes. Conclusion According to the expression of ER, PR, HER2 and CK5/6, infiltrative ductal carcinoma could be subclassified into five subgroups with different biological features and outcome, having a role in evaluating the prognosis and guiding the clinical treatment.

关 键 词：乳腺肿瘤 癌 导管 乳腺 免疫表型分型 无病生存 

分 类 号：R737.9[医药卫生—肿瘤]